Increasing access to safe abortion services in rural India: experiences with medical abortion in a primary health center

被引:31
作者
Mundle, Shuchita
Ejul, Batya
Anand, Abhijeet
Kalyanwala, Shveta [1 ]
Ughade, Suresh
机构
[1] Populat Council, India Habitat Ctr, New Delhi 110003, India
[2] Govt Med Coll, Dept Obstet & Gynaecol, Nagpur 440003, Maharashtra, India
[3] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA
[4] Populat Council, Formerly, New Delhi 110003, India
[5] Govt Med Coll, Dept Prevent & Social Med, Nagpur 440003, Maharashtra, India
关键词
medical abortion; mifepristone; misoprostol; primary health centers; India;
D O I
10.1016/j.contraception.2007.03.010
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Introduction: To increase access to safe abortion in rural India, the feasibility and acceptability of mifepristone-misoprostol abortion was assessed in a typical government run primary health center (PHC) in Nagpur district, Maharashtra State, that does not offer surgical abortion services and must refer off-site for emergency and backup services. Materials and Methods: Consenting pregnant women (n=149) with <= 56 days amenorrhea seeking terminations received 200 mg mifepristone, and returned 48 h later for 400-mu g sublingual misoprostol and 12 days later for abortion confirmation. Surgical backup was conducted at a nearby community health center (CHC). Results: Nearly all women (98.6%) with known outcomes had successful medical abortions, and those who did not (1.4%) were successfully referred to the CHC for surgical backup. Women reported the method's ease and simplicity as the best features. Conclusion: Medical abortion provision is feasible and acceptable in an Indian rural PHC that does not offer surgical abortion services. This study suggests that introduction of medical abortion at lower levels of the health-care system could increase access to safe abortion in rural India. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:66 / 70
页数:5
相关论文
共 15 条
  • [1] Mifepristone-misoprostol abortion: a trial in rural and urban Maharashtra, India
    Coyaji, K
    Elul, B
    Krishna, U
    Otiv, S
    Ambardekar, S
    Bopardikar, A
    Raote, V
    Ellertson, C
    Winikoff, B
    [J]. CONTRACEPTION, 2002, 66 (01) : 33 - 40
  • [2] Mifepristone abortion outside the urban research hospital setting in India
    Coyaji, K
    Elul, B
    Krishna, U
    Otiv, S
    Ambardekar, S
    Bopardikar, A
    Raote, V
    Ellertson, C
    Winikoff, B
    [J]. LANCET, 2001, 357 (9250) : 120 - 122
  • [3] Side effects of mifepristone-misoprostol abortion versus surgical abortion - Data from a trial in China, Cuba, and India
    Elul, B
    Ellertson, C
    Winikoff, B
    Coyaji, K
    [J]. CONTRACEPTION, 1999, 59 (02) : 107 - 114
  • [4] Can women in less-developed countries use a simplified medical abortion regimen?
    Elul, B
    Hajri, S
    Nguyen, TNN
    Ellertson, C
    Ben Slama, C
    Pearlman, E
    Winikoff, B
    [J]. LANCET, 2001, 357 (9266) : 1402 - 1405
  • [5] *GOV IND, 1990, SURV CAUS MAT DEATHS
  • [6] Khan ME, 1999, IMPLEMENTING REPROD, P507
  • [7] Early abortion by mifepristone (RU 486) followed by vaginal gel (meteneprost) versus oral (misoprostol) prostaglandin
    Takkar, D
    Agarwal, N
    Sehgal, R
    Buckshee, K
    [J]. ADVANCES IN CONTRACEPTION, 1999, 15 (02) : 163 - 173
  • [8] A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation
    Tang, OS
    Chan, CCW
    Ng, EHY
    Lee, SWH
    Ho, PC
    [J]. HUMAN REPRODUCTION, 2003, 18 (11) : 2315 - 2318
  • [9] Pharmacokinetics of different routes of administration of misoprostol
    Tang, OS
    Schweer, H
    Seyberth, HW
    Lee, SWH
    Ho, PC
    [J]. HUMAN REPRODUCTION, 2002, 17 (02) : 332 - 336
  • [10] VANLOOK PFA, 1993, BRIT MED J, V307, P532